Abstract Objectives Diabetes mellitus is a chronic metabolic condition marked by high blood sugar levels. As a primary treatment for type 2 diabetes (T2DM), metformin has demonstrated positive effects on antioxidant and anti-inflammatory biomarkers in newly diagnosed patients. Methods This was a prospective observational study. Blood samples were collected three times to analyse biomarkers. The study involved newly diagnosed T2DM patients who provided written informed consent. The assessments included plasma lipid peroxidation, superoxide dismutase (SOD), catalase, and Malondialdehyde (MDA) levels. Additionally, interleukin-6 (IL-6) was measured to evaluate inflammation. Results HbA1c levels significantly decreased at the 6-month follow-up. Analysis showed a reduction in SOD levels at each visit, with a statistically significant difference between the first and second follow-ups (p=0.03028). MDA levels also decreased at each visit, with a statistically significant difference between the first and second follow-ups (p<0.05). Catalase levels increased at each visit, but only between the first and second follow-ups (p=0.03124). IL-6 levels decreased at each visit, with a statistically significant difference between the first and second follow-ups (p<0.05). Conclusions Metformin reduces oxidative stress and inflammation in patients with type 2 diabetes, aiding in protecting cells and tissues.
MISRA et al. (Wed,) studied this question.